Resveratrol, Polyphenols, and Longevity: SIRT1, Bioavailability, and What Actually Works in Humans

Updated: June 2026resveratrol benefits · resveratrol longevity · SIRT1 activator · polyphenols health · resveratrol bioavailability · pterostilbene vs resveratrol · quercetin longevity · EGCG green tea extract · fisetin senolytic · resveratrol supplement · French paradox · resveratrol anti-aging · polyphenol supplement · curcumin bioavailability
15%
median lifespan extension in mice with resveratrol 100mg/kg/day — Baur 2006 (Nature, N=mice on high-fat diet): resveratrol reversed many metabolic consequences of high-fat feeding and extended median lifespan 15% vs untreated high-fat-diet controls; SIRT1 activation was the proposed mechanism; critically, this was in obese mice on a high-fat diet — subsequent studies in lean mice (Pearson 2008, Cell Metabolism) showed resveratrol did not extend lifespan in healthy-weight animals; the effect may be specific to metabolic rescue, not general longevity; human doses achieving equivalent tissue concentrations would require >1g/day, far above standard supplement doses
1%
oral bioavailability of resveratrol in humans without fat co-administration — resveratrol undergoes rapid and extensive first-pass metabolism in the intestine and liver; sulfation and glucuronidation convert most resveratrol to inactive metabolites before it reaches systemic circulation; Walle 2004 (Annals of the New York Academy of Sciences): after 25mg oral dose, peak plasma resveratrol was 0.6–2 μg/mL for only 30–60 minutes; food (fat specifically) increases absorption 3–5×; liposomal or micronized formulations improve bioavailability 4–8×; this is the central limitation of resveratrol as a supplement — the doses producing SIRT1 activation in vitro require concentrations that cannot be achieved with oral administration
better bioavailability of pterostilbene vs resveratrol — pterostilbene is a natural analog of resveratrol found in blueberries and grapes; two methyl groups replace hydroxyl groups, dramatically reducing first-pass sulfation; Kapetanovic 2011: pterostilbene achieved 4× higher plasma concentrations than resveratrol at equal doses; also more lipophilic (better cell membrane penetration); similar SIRT1 activation to resveratrol in cellular models; 50–100mg pterostilbene achieves plasma concentrations roughly equivalent to 250–400mg resveratrol; considered by many researchers the superior resveratrol alternative, though human longevity data is similarly limited
SIRT1
sirtuin-1 — the NAD+-dependent deacetylase proposed as resveratrol's primary longevity target; SIRT1 deacetylates and activates PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance genes), and p53 (DNA repair and apoptosis regulation); in caloric restriction, NAD+ levels rise (fewer calories metabolized → less NAD+ consumed), which activates SIRT1; Sinclair's original 2003 proposal: resveratrol activates SIRT1 allosterically, mimicking caloric restriction; controversy: Pfizer researchers (Borra 2005; Kaeberlein 2005) argued the SIRT1 activation was an assay artifact; Sinclair's group responded with alternative evidence; the debate remains unresolved; SIRT1 activation from polyphenols in human tissue at achievable concentrations has not been definitively demonstrated

The French Paradox — the observation that French populations have relatively low cardiovascular disease mortality despite high saturated fat intake — was proposed in 1991 to be partially explained by red wine consumption and specifically resveratrol. This hypothesis launched two decades of resveratrol research. The mechanism was compelling: resveratrol activates SIRT1, a key longevity regulator also activated by caloric restriction, and produces broad protective effects in cellular and animal models. However, the translation to humans has been repeatedly complicated by the bioavailability problem — resveratrol is rapidly metabolized, the doses required to achieve cellular concentrations that activate SIRT1 are far above what supplements typically deliver, and the clinical trial results have been mixed.

This does not mean polyphenols are without value in human health. The epidemiological data linking high dietary polyphenol intake to reduced disease risk is substantial. The question is mechanism: are polyphenols extending health via SIRT1 and longevity pathways, or primarily via antioxidant, anti-inflammatory, and gut microbiome-modulating effects? For practical purposes, this mechanistic question matters less than the evidence for specific outcomes — and the evidence for specific polyphenols in specific applications is the most actionable frame.

Polyphenol Comparison Table — Evidence Tier, Bioavailability, and Best Application
PolyphenolPrimary MechanismBest Human EvidenceBioavailabilityDoseEvidence Tier
QuercetinSenolytic (clears senescent cells); anti-inflammatory (NF-κB inhibition); zinc ionophoreKirkland 2019 pilot (N=14): quercetin + dasatinib reduced senescent cell burden; anti-inflammatory in OA and allergiesPoor alone; improved with bromelain or phospholipid complex500–1000mg with bromelainStrong senolytic pilot; good anti-inflammatory; longevity mechanistic evidence promising but limited RCTs
FisetinPotent senolytic; SIRT1 activator; anti-inflammatoryYousefzadeh 2018 (EBioMedicine): fisetin most potent senolytic of 10 polyphenols tested in mice; extended median lifespan 10%; pilot human data (Mayo Clinic) in older adults pending publicationLow; fat-soluble; take with food100–500mg with fatty meal; pulse dosing (2–3 days/month senolytic protocol)Best animal senolytic data; limited human RCTs; among the most promising polyphenols for longevity
EGCG (green tea)AMPK activation; autophagy induction; anti-inflammatory; catechol methyltransferase inhibition → increased norepinephrineNumerous RCTs in metabolic health; modest weight loss, cholesterol reduction; anti-cancer in prospective studies (Japanese green tea consumption data)Moderate; better absorbed fasted; standardized extract (50% EGCG) more reliable than brewed tea300–600mg EGCG; cycle off monthly (liver caution at high doses continuous)Strong anti-inflammatory and metabolic evidence; longevity pathway activation well-supported mechanistically; hepatotoxicity risk at >800mg/day requires caution
PterostilbeneSIRT1 activation; anti-inflammatory; PPAR-α agonism (fat oxidation); blood glucose reductionMacRae 2013 (J Agric Food Chem): 50mg/day reduced LDL and blood pressure in adults; limited longevity RCTs but mechanistically superior to resveratrolHigh vs resveratrol; 4× better bioavailability50–100mg/dayMechanistically strong; better bioavailability than resveratrol; limited large human RCTs; preferred over resveratrol by many researchers
ResveratrolSIRT1 activation (debated); NF-κB inhibition; AMPK activation; autophagy inductionTimmers 2011 (Cell Metabolism, N=11): 150mg/day in obese men: improved insulin sensitivity, mitochondrial function, reduced BP; BUT Poulsen 2013 (J Physiol, N=27): resveratrol blocked exercise adaptation improvements; mixed results in cancer and cardiovascular human trialsVery low (1%) without fat; micronized or liposomal formulations substantially better500mg–1g/day with fat; use micronized formStrong mechanistic story; mixed human RCT evidence; bioavailability is the central limitation; pterostilbene is likely superior
CurcuminNF-κB inhibitor; COX-2 inhibitor; AMPK activation; Nrf2 activationMeta-analysis 2021 (Phytotherapy Research, 32 RCTs): curcumin significantly reduced CRP, IL-6, TNF-α; OA pain comparable to NSAIDs in some trials; depression adjunct therapy signalVery low alone (<1%); piperine 20mg increases 2,000%; liposomal (Meriva) or BCM-95 formulations achieve 6–8× standard powder500–2000mg + 20mg piperine or use liposomal formStrongest anti-inflammatory polyphenol evidence in humans; longevity pathway activation plausible; requires enhanced formulation for any meaningful absorption
Practical Polyphenol Protocol — Stack by Goal

General longevity / anti-aging foundation: Fisetin 500mg with fatty meal 2–3 consecutive days per month (senolytic pulse dosing, Mayo Clinic protocol framework); pterostilbene 50mg daily (SIRT1 activation, better bioavailability than resveratrol); EGCG 400mg in the morning (AMPK activation, autophagy support); quercetin 500mg with bromelain daily (anti-inflammatory, additional senolytic activity on non-fisetin days).

Ready to build the full protocol?
The Longevity Stack ranks 20+ compounds by evidence tier — the full biomarker panel, VO2 max protocol, sleep science, hormone chapter, and three budget-level stacks, built from the same research on this page.
Get the Longevity Stack → $19

Anti-inflammatory focus: Curcumin 1000mg + piperine 20mg with largest meal (NF-κB, COX-2 inhibition); EGCG 300–600mg fasted or with minimal food; quercetin 500mg; omega-3 EPA+DHA 2–4g (synergistic anti-inflammatory via eicosanoid modulation). This stack addresses multiple inflammatory pathways simultaneously.

Food-first polyphenol strategy (pragmatic alternative): The diet highest in polyphenols by ORAC score: blueberries, blackberries, pomegranate, dark chocolate (>70% cacao), green tea, extra virgin olive oil, red wine (moderate), turmeric, cloves, and dried herbs. 30+ plant foods/week provides diverse polyphenol exposure across flavonoids, stilbenes, phenolic acids, and lignans. Supplementation is additive to food sources, not a substitute for dietary polyphenol diversity.

Cautions: EGCG >800mg/day continuous use has been associated with liver enzyme elevation in case reports — cycle off 1 week per month; quercetin may interfere with thyroid hormone absorption (take 2+ hours apart from thyroid medication); curcumin may increase bleeding risk at high doses; resveratrol may antagonize exercise adaptation at high doses (Poulsen 2013) — take on rest days if this is a concern.

Pterostilbene → Fisetin →

More longevity protocols

Senolytics → NAD+ & NMN → Autophagy & Fasting → Cold & Sauna →

As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.